Therapeutic use of anti-CS1 antibodies

Details for Australian Patent Application No. 2004318675 (hide)

Owner Abbott Biotherapeutics Corp.

Inventors Dubridge, Robert B.; Powers, David B.; Tso, J. Yun; Williams, Marna; Landolfi, Nicholas F.; Law, Debbie; Liu, Gao

Agent Davies Collison Cave

Pub. Number AU-B-2004318675

PCT Pub. Number WO2005/102387

Priority 60/557,621 29.03.04 US; 10/842,011 07.05.04 US; 10/982,357 05.11.04 US; 60/557,622 29.03.04 US; 60/557,620 29.03.04 US

Filing date 8 November 2004

Wipo publication date 3 November 2005

Acceptance publication date 16 June 2011

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

Event Publications

26 October 2006 PCT application entered the National Phase

  PCT publication WO2005/102387 Priority application(s): WO2005/102387

22 October 2009 Assignment before Grant

  PDL BioPharma, Inc. The application has been assigned to Facet Biotech Corporation 2005

27 January 2011 Alteration of Name

  The name of the applicant has been altered to Abbott Biotherapeutics Corp. Amendments 2005

16 June 2011 Application Accepted

  Published as AU-B-2004318675

13 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004318679-Methods and systems for voter-verified secure electronic voting

2004318670-An innovative screening method for coronary heart disease and stroke